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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.021The deposition of amyloid-b peptides (Ab) in the cerebral vasculature, a condition known as
cerebral amyloid angiopathy, is increasingly recognized as an important component leading to
intracerebral hemorrhage, neuroinﬂammation, and cognitive impairment in Alzheimer disease (AD)
and related disorders. Recent studies demonstrated a role for the bradykinin B1 receptor (B1R) in
cognitive deﬁcits induced by Ab in mice; however, its involvement in AD and cerebral amyloid
angiopathy is poorly understood. Herein, we investigated the effect of B1R inhibition on AD-like
neuroinﬂammation and amyloidosis using the transgenic mouse model (Tg-SwDI). B1R expression
was found to be up-regulated in brains of Tg-SwDI mice, speciﬁcally in the vasculature, neurons,
and astrocytes. Notably, administration of the B1R antagonist, R715, to 8-month-old Tg-SwDI mice
for 8 weeks resulted in higher Ab40 levels and increased thioﬂavin Sepositive ﬁbrillar Ab depo-
sition. Moreover, blockage of B1R inhibited neuroinﬂammation, as evidenced by the decreased
accumulation of activated microglia and reactive astrocytes, diminished NF-kB activation, and
reduced cytokine and chemokine levels. Together, our results indicate that B1R activation plays an
important role in limiting the accumulation of Ab in AD-like brain, likely through the regulation of
activated glial cell accumulation and release of pro-inﬂammatory mediators. Therefore, the
modulation of the receptor may represent a novel therapeutic approach for AD. (Am J Pathol 2013,
182: 1740e1749; http://dx.doi.org/10.1016/j.ajpath.2013.01.021)Supported by National Institute of Aging grant AG020241 (D.H.C.),
National Institute of Neurological Disorders and Stroke grant NS050895
(D.H.C.), Program Project grant PO1 AG00538 (F.M.L. and D.H.C.), and
Alzheimer’s Association grant IIRG11-204835 (D.H.C.). Anti-Ab40 and
anti-Ab42 antibodies and Ab40 and Ab42 peptides were provided by the
University of California, Irvine, Alzheimer’s Disease Research Center
through funding from NIH/National Institute of Aging grant P50 AG16573.The progressive accumulation of amyloid-b (Ab) in the brain
is a prominent feature of Alzheimer disease (AD) and related
disorders, together with neuroﬁbrillary tangles, cognitive
decline, and chronic inﬂammation.1,2 Ab is a 36e to
43eamino acid peptide, which is produced by sequential
enzymatic cleavage of the amyloid precursor protein (APP)
by b- and g-secretases.1 Overproduction, altered processing,
or failure of clearance by cellular uptake and degradation or
transport across the blood-brain barrier (BBB) have been
shown to cause the accumulation of Ab in the form of plaques
in brain parenchyma and in walls of cerebral vessels as
cerebral amyloid angiopathy (CAA).3,4 In contrast to
parenchymal plaques, which can be composed of either
diffuse or ﬁbrillar deposits, cerebral vascular Ab deposits are
largely of ﬁbrillar form.5 Several studies have shown that
cerebral vascular Ab deposits are associated with a localized
neuroinﬂammatory response and cognitive impairment, andstigative Pathology.
.it has been suggested that microvascular Ab accumulation is
a better correlate with dementia than parenchymal amyloid
plaques in individuals with AD and CAA.6e11
CAA is the major pathological feature of several familial
disorders involving speciﬁc point mutations within the Ab
region of the APP gene, including the Dutch type (E22Q) and
the Iowa type (D23N), which cause early and severe cerebral
vascular amyloid deposition.12e14 A transgenic mouse model
(Tg-SwDI) has been generated expressing human Swedish/
Dutch/Iowa triple-mutant APP in the brain.15 The resulting
Bradykinin B1R Regulates AD PathologyDutch/Iowa mutant Ab presents highly vasculotropic prop-
erties and low efﬁciency for BBB transport, thus resulting in
early-onset and robust deposition of cerebral microvascular
amyloid and diffuse parenchymal Ab.16e18 In addition, Tg-
SwDI mice exhibit marked neuroinﬂammation and behav-
ioral deﬁcits, providing a valuable experimental paradigm to
study selective accumulation of cerebral vascular amyloid
and potential therapeutic interventions in CAA.19,20
Kinins are a family of biologically active peptides generated
at the sites of tissue damage in response to trauma or infection,
or during most inﬂammatory processes.21 The role of kinins
has been described in numerous systems, and their main
pharmacological effects include smooth muscle contraction
and relaxation, vasodilatation, increase in vascular perme-
ability, cell recruitment, and sensitization of nociceptive
ﬁbers.22e24 Kinins exert their actions through the stimulation
of two different G-proteinecoupled receptors, classiﬁed as B1
and B2.
24 The B2 receptor is constitutively expressed in central
and peripheral mammalian tissues, mediating most of the
physiological actions evoked by kinins and exhibiting high
afﬁnity for bradykinin and kallidin. In contrast, the B1 receptor
(B1R) shows higher afﬁnity for the metabolites des-Arg
9-
bradykinin and des-Arg10-kallidin and is present at low levels
under normal conditions, but can be strongly up-regulated
after tissue trauma, during certain inﬂammatory states, or by
the action of pro-inﬂammatory cytokines or bacterial prod-
ucts.25 Therefore, inappropriate B1R expression has been
suggested to have a pivotal role in several chronic diseases
involving pain and inﬂammation.22,23,26 Recently, it has been
demonstrated that the intracerebral administration of Ab40 in
rodents results in up-regulation of B1R expression in brain
regions related to cognitive behavior, and that blockade of B1R
signaling improves Ab-induced cognitive deﬁcits, suggesting
the involvement of the kinin system in AD.27e29
Given the important role of B1R in mediating vascular
function and inﬂammatory processes, in the present study, we
investigated the effect of selective pharmacological blockade
of B1R on Ab deposition and neuroinﬂammation in Tg-SwDI
mice. We observed a marked up-regulation of the receptor
expression in Tg-SwDI brains, and the blockade of B1R
activation resulted in increased ﬁbrillar Ab deposition. In
addition, we found a reduced neuroinﬂammatory response in
mice treated with the B1R antagonist, as demonstrated by
a marked decrease of microglial and astrocytic activation and
diminished levels of pro-inﬂammatory mediators. Together,
these results provide evidence that the B1R is involved in
the regulation of Ab deposition and neuroinﬂammation, and
suggest that this receptor could be a new target for the
treatment of AD.
Materials and Methods
Animals and Treatments
Tg-SwDI line B mice that express the human APP770 cDNA
containing the Swedish (KM670/671NL), Dutch (E693Q),The American Journal of Pathology - ajp.amjpathol.organd Iowa (D694N) mutations were used in this study.15,20
Tg-SwDI mice and non-transgenic (nTg) C57Bl/6 mice
(nZ 8 for each group) were 8 months of age at the beginning
of the study. All experiments followed the NIH guidelines
and were approved by the University of California, Irvine,
Institutional Animal Care and Use Committee.
The pharmacological modulation of the B1Rwas performed
using 1 mg/kg selective antagonist Ac-Lys-[D-b Nal,7 Ile8]
des-Arg9-bradykinin (R715; Biomatik, Wilmington, DE),
given as daily s.c. injections for 8 weeks.30,31 Control mice
received vehicle (0.9% NaCl solution).
Behavioral Tests
Novel object and novel place recognition tests were used to
evaluate cognition. Each mouse was habituated to an empty
arena for 5 minutes 1 day before testing. On the ﬁrst day of
novel object testing, mice were exposed to two identical
objects placed at opposite ends of the arena for 5 minutes.
Twenty-four hours later, the mouse was returned to the
arena, this time with one familiar object and one novel
object. Time spent exploring the objects was recorded for 5
minutes. For the place recognition test, each mouse was
placed in the arena with two identical objects evenly spaced,
and allowed to explore for 5 minutes. After 24 hours, mice
were placed in the arena for 5 minutes with one object
displaced to a new location, whereas the other object was
not moved. The recognition index represents the percentage
of the time that mice spend exploring the novel or moved
object. Objects used in this task were carefully selected to
prevent preference or phobic behavior.
Tissue Preparation
Mice were deeply anesthetized with sodium pentobarbital
and euthanized by transcardial perfusion with 0.1 mol/L ice-
cold PBS solution (pH 7.4). The right brain hemispheres
were ﬁxed for 24 hours in 4% paraformaldehyde and cry-
oprotected in 30% sucrose for immunohistochemical (IHC)
analysis. Frozen brains were divided into sections coronally
(40 mm thick) using a Leica SM2010R freezing microtome
(Leica Microsystems, Bannockburn, IL), serially collected in
cold 0.02% sodium azide in PBS, and stored at 4C. The left
hemispheres were snap frozen on dry ice and subjected to
protein extraction using the T-PER tissue protein extraction
reagent (Thermo Scientiﬁc, Rockford, IL) and 70% formic
acid. The supernatant was divided and stored at 80C. The
protein concentration in the supernatant was determined
using the BCA Protein Assay kit (Thermo Scientiﬁc).
Western Blot Analysis
Equal protein amounts were separated on a 4% to 12% SDS-
PAGE gradient, transferred to a nitrocellulose membrane, and
incubated overnight with primary antibodies at 4C. The
following primary antibodies were used: human APP-CT20,1741
Passos et aldisintegrin and metalloproteinase domainecontaining protein
(ADAM)10, ADAM17, b-site APP-cleaving enzyme 1
(BACE1; Calbiochem, San Diego, CA), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), B1R (Santa Cruz
Biotechnology, Santa Cruz, CA), low-density lipoprotein
receptorerelated protein 1 (LRP1), apolipoprotein E (APOE),
neprilysin (Abcam, Cambridge, MA), phosphorylated-p65
NF-kB, liver X receptor, peroxisome proliferator-activated
receptor g, and matrix metalloproteinase-9 (Cell Signaling
Technology, Danvers, MA). After washing, the membranes
were incubated with adjusted secondary antibodies coupled to
horseradish peroxidase. The immunocomplexes were visual-
ized using the SuperSignal West Pico Kit (Thermo Scientiﬁc).
Band density measurements were obtained using ImageJ
imaging software version 1.36b (NIH, Bethesda, MD).ELISA Analysis
For the determination of Ab levels, T-PER soluble fractions
were loaded directly onto enzyme-linked immunosorbent
assay (ELISA) plates, whereas the formic acid supernatants
(insoluble fractions) were diluted 1:40 in a neutralization
buffer (1 mol/L Tris base and 0.5 mol/L NaH2PO4) before
loading. Immulon 2HB immunoassay plates (Thermo Scien-
tiﬁc) were coated with mAb20.1 antibody at a concentration of
25 mg/mL in coating buffer (0.1 mol/L NaHCO3/Na2CO3
buffer, pH 9.6) and blocked with 3% bovine serum albumin
(BSA). Standard solutions for both Ab40 and Ab42 were made
in antigen capture buffer (20 mmol/L Na3PO4, 2 mmol/L
EDTA, 0.4 mol/L NaCl, 0.05% 3-[(3-cholamidopropyl)
dimethylammonio]propanesulfonate, 1% BSA, and 0.05%
sodium azide, pH 7.0) and loaded onto ELISA plates in
duplicate. Samples were then loaded (in duplicate) and incu-
bated overnight at 4C. Plates were washed and probed with
either biotinylated monoclonal anti-Ab40 (C49) or anti-Ab42
(D32) antibodies (Alzheimer’s Disease Research Center at the
University ofCalifornia, Irvine) in detection buffer (20mmol/L
Na3PO4, 0.4 mol/L NaCl, 2 mmol/L EDTA, 1% BSA, and
0.002% thimerosal, pH 7.0) overnight at 4C. Streptavidine
horseradish peroxidase (1:4000; Thermo Scientiﬁc) in detec-
tion buffer was added and incubated at 37C for 4 hours. Plates
were developed with the addition of Ultra TMB-ELISA subs-
trate (Thermo Scientiﬁc), followed by 0.8 mol/LO-phosphoric
acid to stop the reaction. The plates were read at 450 nm using
a plate reader (Molecular Dynamics, Sunnyvale, CA). The
readings obtainedwere normalized to the protein concentration
of the samples.Cytokine Protein Array
The expression of multiple cytokines/chemokines was
assessed using the Proteome Proﬁler mouse cytokine array
panel A (R&D Systems, Minneapolis, MN), according to
manufacturer’s instructions. Densitometric analysis of the
dot blots was performed using ImageJ version 1.36b (NIH).1742IHC Data
Antigen retrieval was optimized using a 90% formic acid
solution for 7 minutes for Ab staining. Free-ﬂoating sections
were pretreatedwith 3% hydrogen peroxide and 10%methanol
in Tris-buffered saline (TBS) for 30 minutes to block endog-
enous peroxidase activity. After a TBS wash, sections were
incubated once in 0.1% Triton X-100 (Fisher Scientiﬁc, Pitts-
burgh, PA) in TBS for 15 minutes and once with 2% BSA in
0.1% Triton-X in TBS for 30 minutes. Sections were then
incubated overnight at 4C with biotinylated anti-Ab42 (D32)
or anti-Ab40 (C49) antibodies, or with anti-glial ﬁbrillary acidic
protein (GFAP; Millipore, Billerica, MA), anti-CD68, anti-
CD11b, or anti-CD45 (IBL-3/16; AbD Serotec, Raleigh, NC)
antibodies with 5% normal serum in TBS. After incubation
with the appropriate biotinylated secondary antibody for 2
hours, sections were processed using the Vectastain Elite ABC
reagent and 3,30-diaminobenzidine (Vector Laboratories, Bur-
lingame, CA), according to the manufacturer’s instructions.
Sections were then mounted on gelatin-coated slides, dehy-
drated in graded ethanol, cleared in xylene, and coverslipped
with DPXmountingmedium (VWR International, Poole, UK).
The immunostaining was assessed at six brain coronal
levels. Speciﬁcally, six alternate sections (40 mm thick) of
the brain, with an individual distance of approximately 160
mm, were obtained between 1.34 and 2.54 mm posterior to
the bregma. Images of stained subiculum, hippocampus,
dentate gyrus, frontotemporal cortex, and thalamus were
acquired using an Axiocam digital camera and AxioVision
software version 4.6 connected to an Axioskop 50 micro-
scope (Carl Zeiss MicroImaging, Thornwood, NY). The
obtained images were analyzed using ImageJ 1.36b (NIH),
and data are reported as the labeled area captured (positive
pixels)/the full area captured (total pixels). All assessments
were performed by examiners (G.F.P. and R.M.) blinded to
sample identities.
Immunoﬂuorescence
Sections were ﬁrst blocked with 3% normal serum, 2% BSA,
and 0.1% Triton X-100 in TBS for 1 hour at room temperature.
By using the same buffer solution, sections were incubated
overnight at 4C with the following primary antibodies: antie
Ab1-16 (6E10; Covance Research Products, San Diego, CA),
anti-collagen IV, anti-GFAP (Abcam), antieIba-1 (Wako
Chemicals, Richmond, VA), anti-NeuN (Millipore), and/or
anti-B1R (Novus Biologicals, Littleton, CO). In some experi-
ments, sections were also incubated with biotinylated tomato
lectin (Vector Laboratories). Sections were then rinsed and
incubated for 1 hour at room temperature with secondary Alexa
Fluoreconjugated antibodies (Invitrogen, Carlsbad, CA) or
Alexa Fluoreconjugated streptavidin (Molecular Probes,
Eugene, OR), when needed. Finally, sections were mounted
onto gelatin-coated slides in Fluoromount-G (Southern Biotech,
Birmingham, AL) and examined under a Leica DM2500
confocal laser microscope using Leica Application Suiteajp.amjpathol.org - The American Journal of Pathology
Bradykinin B1R Regulates AD PathologyAdvanced Fluorescence software version 2.6.0 (Leica Micro-
systems, Wetzlar, Germany).Thioﬂavin S Staining
Sections were incubated with 0.5% thioﬂavin S in 50%
ethanol for 10 minutes, washed twice with 50% ethanol,
followed by washing with PBS solution. Staining was visu-
alized under a confocal microscope. Image measurementsThe American Journal of Pathology - ajp.amjpathol.orgwere made using ImageJ version 1.36b (NIH). The thioﬂavin
S levels represent the average value obtained by the analysis
of images of the subiculum, dentate gyrus, and thalamus.
Statistical Analysis
All data are expressed as means  SEM. Statistical evalu-
ation of the results was performed using one- or two-way
analysis of variance. After signiﬁcant analyses of variance,
multiple post hoc comparisons were performed using Bon-
ferroni’s test. Some data were analyzed using the unpaired
t-test. The accepted level of signiﬁcance for the tests was
P < 0.05. All tests were performed using the Statistica
software package (StatSoft Inc., Tulsa, OK).
Results
Bradykinin B1R Expression Is Up-Regulated in Tg-SwDI
Brain
In aﬁrst set of experiments,we assessed the expressionofB1R in
brains from 10-month-old nTg C57Bl/6 and Tg-SwDI mice
usingWestern blot and immunoﬂuorescence confocal analyses.
The B1R was constitutively expressed in nTg mice, primarily in
neurons. In contrast, strikingly increased levels of B1R were
observed in Tg-SwDI brains, with neurons, astrocytes, and
vascular cells expressing elevated levels of the receptor
(Figure 1, AeC). Notably, up-regulation in B1R expression was
found in subiculum, dentate gyrus, cortex, and thalamus
(Figure 1D). Moreover, B1R expression up-regulation was
found to be widely associated with Ab deposition, as demon-
strated by confocal colocalization analysis of B1R, vasculature
(tomato lectin), and Ab (6E10) (Figure 1E). Taken together,
these data demonstrate that Ab deposition is linked to the up-
regulation of B1R, suggesting a role for this receptor in the
neuropathological alterations observed in the Tg-SwDI model.
Bradykinin B1R Up-Regulation Affects Ab Deposition
The Tg-SwDImice are characterized by early-onset and robust
accumulation of Ab in the brain, predominantly in the cerebralFigure 1 B1R is up-regulated in Tg-SwDI brain. Representative blots
(A) and quantitative results (B) of Western blot analysis showing the
increased expression of B1R in the brains of 10-month-old Tg-SwDI mice
compared with age-matched nTg animals. GAPDH levels were used as
loading controls. C: In nTg mice, confocal analysis demonstrated the
colocalization of B1R (red) and NeuN-positive (green) neurons, and
elevated immunoreactivities of B1R (red) colocalized with NeuN-positive
neurons, collagen IVepositive vessels, and GFAP-positive astrocytes (all
green) were observed in Tg-SwDI mice. Representative photomicrographs
were taken from hippocampus (Hip; NeuN/B1R), dentate gyrus (GFAP/
B1R), and thalamus (collagen IV/B1R). D: B1R immunoreactivity was
increased in cortex (Ctx), thalamus (Tha), dentate gyrus (DG), and sub-
iculum (Sub) of Tg-SwDI versus nTg mice. E: Confocal laser microscopy of
B1R (red), tomato lectin (green), and 6E10 (blue) demonstrated the
colocalization of the B1R and the vasculature in areas of Ab deposits
(6E10) in the brains of Tg-SwDI mice. Representative photomicrographs
were taken from the thalamus. Scale bar Z 10 mm. The values represent
means  SEM (N Z 5 to 6). *P < 0.05, **P < 0.01.
1743
Figure 2 B1R up-regulation affects Ab deposition in Tg-SwDI brain. Mice s.c. treated with 1 mg/kg R715 for 8 weeks have no changes in the levels of Ab40
in the detergent-soluble fraction (A), whereas increased levels of Ab40 were observed in the detergent-insoluble fraction (B), and both detergent-soluble (C)
and detergent-insoluble (D) Ab42 levels remained unchanged, as measured by ELISA. E and F: Ab40 immunoreactivity was increased in cortex (Ctx), thalamus
(Tha), hippocampus (Hip), dentate gyrus (DG), and subiculum (Sub) of R715-treated mice when compared with the vehicle-treated group. E and G: R715
administration had no effect on Ab42 immunoreactivity in Tg-SwDI brains. Representative photomicrographs (H) and quantitative results (I) demonstrating
increased thioﬂavin Sepositive ﬁbrillar Ab deposits in R715-treated mice. Representative photomicrographs were taken from subiculum (E) and thalamus (H).
Scale bars: 10 mm (E); 15 mm (H). The values represent means  SEM (N Z 5 to 6). *P < 0.05, **P < 0.01.
Passos et almicrovasculature.15,17 To assess the possible role of B1R in
Ab deposition in Tg-SwDI mice, we next determined the
levels of Ab40 and Ab42 peptides in both detergent-soluble
and detergent-insoluble fractions by ELISA. The s.c. admin-
istration of 1 mg/kg selective B1R antagonist R715 for 8
weeks, initiated at 8 months of age, resulted in a signiﬁcant
increase in the levels of Ab40 in the detergent-insoluble frac-
tion when compared with vehicle-treated mice (Figure 2B).
Conversely, no signiﬁcant changes in detergent-soluble Ab40
and detergent-soluble and detergent-insoluble Ab42 were de-
tected (Figure 2, A, C, and D). Conﬁrming these data, the IHC
analysis demonstrated increased Ab40 immunoreactivity in the
subiculum, hippocampus, dentate gyrus, cortex, and thalamus
of R715-treated mice, whereas Ab42 levels were unaffected
by B1R blockade (Figure 2, EeG). Moreover, R715 adminis-
tration resulted in strikingly increased thioﬂavin Sepositive
ﬁbrillar Ab deposition (Figure 2, H and I), thus demonstrating
an important role for the B1R in Ab accumulation.
We next aimed to determine the underlying mechanism
by which B1R regulates Ab deposition in Tg-SwDI brain.
As shown in Figure 3, A and B, blockage of B1R did not
change levels of APP or the balance between APP proteolytic
C-terminal fragments (CTF)b (C99) and CTFa (C83). In
addition, expression levels of b-secretase enzyme BACE1 and
a-APP cleaving enzymes ADAM10 and ADAM17 were1744unaltered by R715. Finally, the B1R antagonist was not
capable of affecting themajor putative Ab clearance pathways,
with no changes in LRP1 and APOE expression observed, and
in one of the major Ab-degrading enzymes, neprilysin
(Figure 3, C and D). These data suggest that the B1R modu-
lates Ab accumulation through a mechanism independent of
the regulation of Ab production or BBB- and protease-
mediated clearance.
Bradykinin B1R Blockade Reduces Neuroinﬂammation
in Tg-SwDI
The extensive ﬁbrillar Ab deposition present in cerebral
blood vessels of Tg-SwDI is associated with a strong neu-
roinﬂammatory reaction.19,20,32 Corroborating these data,
we observed pronounced levels of GFAP-positive astrocytes
and CD11b-, CD68-, CD45-, and Iba-1epositive microglia
in vehicle-treated mice (Figure 4, AeD), particularly in
areas with abundant 6E10-positive Ab deposits, as demon-
strated by colocalization studies (Figure 4, C and D). More
important, R715 administration resulted in strikingly
reduced GFAP, CD11b, CD68, CD45, and Iba-1 immuno-
reactivities compared with vehicle-treated mice (Figure 4,
AeD). These data show that B1R plays an essential role in
the glial cell activation observed in Tg-SwDI mice.ajp.amjpathol.org - The American Journal of Pathology
Figure 3 B1R blockade is not associated with
changes in APP processing or in levels of LRP1,
APOE, and neprilysin in Tg-SwDI mice. Represen-
tative blots (A) and quantitative results (B) of
Western blot analysis showing that R715 admin-
istration (1 mg/kg, s.c., 8 weeks) causes no
changes in the levels of APP, APP C-terminal
fragments C99 and C83, or APP-cleaving enzymes
BACE1, ADAM10, and ADAM17, compared with
vehicle-treated animals. C and D: Effect of R715
treatment on the expression of LRP1, APOE, and
neprilysin. GAPDH levels were used as loading
controls. The values represent means  SEM (NZ
6 to 8).
Bradykinin B1R Regulates AD PathologyThe inﬂammatory molecules observed in Tg-SwDI brains
may be actively expressed by reactive microglia and astro-
cytes, found in intimate association with cerebral micro-
vascular amyloid.20,33 Because B1R antagonism reduced
glial cell activation, we sought to determine whether the
administration of R715 could also affect the levels of
inﬂammatory mediators. Our data demonstrate that R715
administration reduces the activation of the pro-
inﬂammatory transcription factor NF-kB, without affecting
the anti-inﬂammatory receptors, liver X receptor and
peroxisome proliferator-activated receptor g, as shown by
the marked decrease in phosphorylated-p65 NF-kB levels
compared with vehicle-treated mice (Figure 5, A and B). On
the other hand, the expression of matrix metalloproteinase-9
was not affected by the treatment (Figure 5, A and B). In
addition, the production of 40 different cytokines/chemo-
kines was proﬁled using a cytokine array, and drastically
reduced levels of IL-1a, IL-1b, tumor necrosis factor-a,
CXCL1, CXCL10, chemokine ligand (CCL) 2, CCL3, C5a,
and tissue inhibitor of metalloproteinases-1 were found in
R715-treated versus vehicle-treated mice (Figure 5C).
Bradykinin B1R Blockade Is Not Associated with
Cognitive Alterations in Tg-SwDI
Finally, we attempted to determine whether the effects of
B1R blockade on Ab deposition and neuroinﬂammation wereThe American Journal of Pathology - ajp.amjpathol.orgassociated with changes in cognitive function by using the
novel object and novel place recognition tasks, which are
believed to be primarily dependent on cortex and hippo-
campus, respectively.34,35 Notably, no signiﬁcant difference
was found between control and R715-treated mice (1 mg/kg,
s.c., 8 weeks) in the exploration of the nonfamiliar object in
the novel object recognition task. Likewise, R715 treatment
resulted in no signiﬁcant change in novel place recognition
task performance (data not shown).
Discussion
In the present study, we demonstrated that Ab deposition in
Tg-SwDI mouse brain is associated with a signiﬁcant up-
regulation of the B1R. The pharmacological antagonism of
the receptor markedly increases the deposition of Ab in the
brain, and this event is accompanied by decreased activation
of glial cells and a reduction in the levels of pro-
inﬂammatory molecules, suggesting an important role for
B1R in the regulation of Ab responses and neuro-
inﬂammation in AD.
The Tg-SwDI mouse is a unique model in that it develops
extensive ﬁbrillar Ab deposits primarily in cerebral micro-
vessels, whereas Ab deposits in the brain parenchyma are
predominantly diffuse. In addition, abundant reactive
astrocytes and activated microglia are strongly associated
with the microvascular ﬁbrillar Ab deposits, together with1745
Figure 4 B1R blockade reduces glial cell activation in Tg-SwDI mice. A and B: Tg-SwDI mouse brains s.c. treated with 1 mg/kg R715 for 8 weeks exhibited
a signiﬁcant decrease in GFAP-positive astrocytes and CD68-, CD11b-, and CD45-positive microglia immunoreactivity versus vehicle-treated animals. Confocal
analysis showing the colocalization of 6E10-positive Ab deposits (red) and GFAP-positive astrocytes (green) (C) or Iba-1epositive microglia (green) (D). Repre-
sentative photomicrographs were taken from the subiculum. Scale bars: 50mm (GFAP and CD11b); 10mm (CD45 and CD68); and 25mm (C andD). The values represent
means  SEM (NZ 5 to 6). **P < 0.01. The graph represents the average of inﬂammatory cells on the cortex, dentate gyrus, subiculum, and thalamus.
Passos et alincreased levels of pro-inﬂammatory mediators.20,32,36 The
pro-inﬂammatory cytokines tumor necrosis factor-a and
IL-1b can induce the up-regulation of the B1R both in vitro
and in vivo.37e40 In addition, we and others have previously
demonstrated that Ab40 induces the up-regulation of the
B1R in rodents, particularly in brain regions related toFigure 5 B1R blockade reduces neuroinﬂammation in Tg-SwDI mice. Repre
demonstrating that s.c. administration of 1 mg/kg R715 for 8 weeks reduces the l
proliferator-activated receptor g, or matrix metalloproteinase (MMP)-9, compared
Cytokine expression determined by a cytokine array. Data were quantiﬁed as pixel
represent means  SEM (N Z 4 to 8). *P < 0.05, **P < 0.01.
1746cognitive behavior, suggesting that this receptor could be
up-regulated in AD brain.27e29 In support of this hypoth-
esis, we found signiﬁcantly increased levels of the B1R in
the brain of Tg-SwDI mice compared with nTg animals,
with neurons, astrocytes, and vascular cells showing up-
regulated expression of the receptor, predominantly insentative blots (A) and quantitative results (B) of Western blot analysis
evels of phosphorylated-p65 NF-kB, but not of liver X receptor, peroxisome
with vehicle-treated mice. GAPDH levels were used as loading controls. C:
density and presented as percentage of vehicle-treated controls. The values
ajp.amjpathol.org - The American Journal of Pathology
Bradykinin B1R Regulates AD Pathologyareas of Ab deposition. A similar pattern of expression has
been reported in multiple sclerosis, focal cerebral ischemia,
and traumatic brain injury. Of great relevance, blockade
of the B1R has been shown to be beneﬁcial in these
inﬂammatory disease models, although conﬂicting data have
been reported for multiple sclerosis.31,41e46
In our study, pharmacological blockade of the B1R
resulted in a marked elevation in the amount of insoluble
Ab40, particularly in the cortex, subiculum, dentate gyrus,
and thalamus, together with increased thioﬂavin Sepositive
ﬁbrillar Ab deposits. To our knowledge, this is the ﬁrst
report showing that the B1R is an important regulator of Ab
deposition in the brain. Interestingly, this effect appears to
be independent of alterations in Ab production, because no
change in the levels of APP, ADAM10, ADAM17, BACE1,
C99, and C83 were found in R715-treated mice. More
important, C99 is produced by the cleavage of APP by b-
secretase and is a marker of amyloidogenic APP processing,
whereas cleavage of APP by a-secretase generates the C83
fragment, a marker of the nonamyloidogenic APP process-
ing.2 In addition, we found no changes in the expression of
LRP1, APOE, and neprilysin, suggesting that B1R activa-
tion is not involved in the control of BBB- and protease-
mediated Ab clearance pathways. However, the presence
of the dual Dutch and Iowa mutations within Ab in Tg-
SwDI mice results in low efﬁciency for LRP1-mediated
transport across the BBB, and may possibly contribute to
resistance to degradation by insulin-degrading enzyme and
neprilysin.16,47,48 Therefore, additional experiments using
other APP transgenic models are necessary to better char-
acterize the effect of B1R on Ab clearance. In addition,
changes in uncharacterized clearance mechanisms cannot be
excluded.
To gain further insight into the underlying mechanisms
through which B1R regulates Ab accumulation, the effect of
B1R blockade on glial cell activation was examined.
Notably, the activation of both microglia and astrocytes was
markedly suppressed by R715, providing evidence for the
critical role of the B1R in the control of glial cell responses
in Tg-SwDI mice. Several studies suggest that microglia and
astrocytes have a role in internalizing and degrading
Ab.49e51 Recently, it was demonstrated that increased
inﬁltration and activation of neuroinﬂammatory cells, such
as microglia/macrophages, might contribute to the clearance
of pre-existing Ab deposits after an ischemic lesion in Tg-
SwDI mice.52 Similar results were found in other trans-
genic mouse models. In J20 APP-Tg mice, the inhibition of
microglial activation using minocycline resulted in signiﬁ-
cantly increased Ab deposition in the hippocampus. Simi-
larly, toll-like receptor 4edependent microglial activation
was shown to be necessary to restrict Ab deposition and
preserve cognitive function in TgAPPswe/PS1dE9 mice.53,54
Thus, one possible scenario is that the accumulation of
activated glial cells induced by B1R up-regulation contrib-
utes to a reduction in Ab deposition in the brain through
a phagocytic-mediated clearance mechanism.The American Journal of Pathology - ajp.amjpathol.orgDespite their role in clearing Ab deposits, glial cells can
also secrete several pro-inﬂammatory mediators, including
cytokines, chemokines, complement proteins, and free
radicals, in response to Ab stimulation, therefore contrib-
uting to the inﬂammatory component of AD.55,56 Herein, we
demonstrated that the activation of the B1R is required for
the activation of NF-kB, a transcription factor important for
pro-inﬂammatory mediator production in response to Ab.57
Consistent with this ﬁnding, we observed a striking inhibi-
tion of the expression of a series of pro-inﬂammatory
proteins, including the cytokines IL-1a, IL-1b, and tumor
necrosis factor-a, and the complement protein C5a. The
administration of R715 has been shown to reduce the
production of cytokines in response to focal brain injury.45
Our data also demonstrate that B1R is implicated in the
production of chemokines, because we found reduced levels
of CXCL1, CXCL10, CCL2, and CCL3 in R715-treated
brains. More important, we and others have shown that
the production of CCL3 is involved in glial accumulation in
response to Ab.54,58 In addition, a recent study demon-
strated that activation of CCR2 by CCL2 is essential for
microglia-mediated Ab clearance in Tg2576 mice, because
CCR2 deﬁciency markedly impairs accumulation of
microglia to sites of Ab deposition and accelerates early
disease progression.59
Interestingly, despite the effect of B1R blockade on glial
responses and neuroinﬂammation, we could not ﬁnd any
improvement in the cognitive performance of Tg-SwDI mice
on both novel object and novel place recognition tasks.
Recently, it was demonstrated that minocycline, an anti-
inﬂammatory treatment targeted for microglial activation,
can improve cognitive deﬁcits in this same animal model,
although the authors found no changes in the accumulation
and distribution of Ab.33 In our previous studies using an
Ab40-injected mouse model of neuroinﬂammation, the up-
regulation of the B1R was shown to play an important role
in the cognitive deﬁcits induced by the peptide, as demon-
strated by enhanced Morris water maze performance after
B1R blockade.
27 However, there are signiﬁcant differences
between the mouse models used in our previous and current
studies that may account for the differences observed.
Previously, we used a model of intracerebral Ab40 injection in
which Ab is rapidly cleared and does not accumulate in the
brain, whereas the Tg-SwDI model used in the current study
presents robust cerebral microvascular accumulation of
ﬁbrillar Ab. In view of that, it is possible to suggest that the
lack of cognitive alterations found in our study is related to the
increased accumulation of Ab40 in response to R715 treat-
ment, because both early-onset accumulation of microvas-
cular amyloid and neuroinﬂammation are associated with
behavioral deﬁcits in Tg-SwDI mice.19
Taken together, our data reveal an important role for the
B1R in neuroinﬂammation and in the control of Ab accu-
mulation in Tg-SwDI mice, possibly through the regulation
of glial cell responses. Therefore, the modulation of the
receptor may represent a novel therapeutic approach for AD.1747
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